Skip to content
★ Sign in to follow
Yuyu Pharma, Inc. logo

Yuyu Pharma, Inc. Stock: price and insider trades · South Korea

유유제약

KR·Mcap ₩58.7BHealth Care

No insider purchase over the last 90 days. The latest, by 장홍석, was filed 16 Jun 2026.

Yuyu Pharma, Inc.: what insiders have been doing

Yuyu Pharma, Inc. is a Health Care company. Its directors and officers file their transactions with DART (FSS). In the past year (9 November 2025 to 9 November 2026), 4 filings came from 2 insiders.

Open-market activity splits into 2 purchases and 1 sale; 2 insiders sit on the buying side and 1 insider on the selling side. The amount is not disclosed for 3 filings. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The buyers include 1 senior executive.

For context, the typical company on the same exchange (median of 2,657 companies) published 7 filings over the same period, against 4 filings here. Looking back to 2021, when coverage begins, insiders filed 6 purchases and 3 sales.

The last insider purchase was made public on 16 June 2026, 147 days ago.

In the same sector, recent insider purchases at Dynavox Group AB and Vetoquinol SA also feature in our signals. Source: insider filings from DART (FSS). Past trades are no guide to future returns.

Insider Decl.
67
Thresholds
n/a
Buy Volume
€75,721
6 ops. · all time
Sell Volume
€2M
3 ops. · all time

Who traded when

BuySale
유원상1 buy1 sale
라이노스자산운용1 sale
장홍석1 buy

Since the insiders bought

  • Filed 03 Feb 2026 · 280 days ago · €578
    -13.4%
    Entry ₩4,615 · Close at T+90 ₩3,995

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Fundamental score
Ranked 3,074 of 26,911 companies
72.9
score / 100
Value
89
Quality
57
FCF yld13%
Earn yld14%
EV/EBITDA4.9x
ROE8.9%
Gross mgn38%
Net mgn5.8%
Debt/EBITDA1.6x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

₩3,725
Analyst consensus
·
Income statement
Revenue₩140.9B
Gross profit₩53.9B38% margin
EBITDA₩17.6B12% margin
Net income₩8.2B8.7% margin
Valuation
Beta0.38
Balance sheet & cash
Market cap₩58.7B
Total debt₩27.9B
Free Cash Flow₩7.4B
Debt / Equity19%
Profitability & ownership
ROE8.9%
ROA4.0%
% insiders38.1%
% institutions0.0%
Last declaration on 1 July 2026
Declarations69 total
  • Other
    Other(filed)
    0DART
  • Other
    Other(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART
  • ▲
    상무Executives(filed)
    €5,955est.0DART
    2,686 sharesShareKRXDART:20260616000273
    Canonical exit: 14 Sept 2026 (T+90)
  • ▼
    Executives
    €7,366est.0DART
    3,000 sharesKRXDART:20260421000448
  • ▲
    Executives
    €578est.0DART
    230 sharesKRXDART:20260203000342
    Canonical exit: 4 May 2026 (T+90)
  • ●
    Executives
    Executives
    0DART
  • ▼
    Related company / holdingExecutives
    €1.7Mest.0DART
    572,301 sharesKRXDART:20250529000294
  • ●
    Executives
    Executives
    0DART
  • ▲
    Executives
    €38kest.0DART
    13,371 sharesKRXDART:20241024000333
    Canonical exit: 22 Jan 2025 (T+90)
  • ▲
    Executives
    €27kest.0DART
    8,600 sharesKRXDART:20241018000463
    Canonical exit: 16 Jan 2025 (T+90)
  • ●
    Executives
    0DART
    0KRXDART:20240912000359
  • ▲
    Executives
    €4,039est.0DART
    1,227 sharesKRXDART:20240722000187
    Canonical exit: 20 Oct 2024 (T+90)
  • ▼
    명예회장Executives
    0DART
    ShareKRXDART:20240703000487
  • ●
    Executives
    0DART
    0KRXDART:20240703000471
  • ▲
    대표이사 사장Executives
    0DART
    ShareKRXDART:20240703000492
    Canonical exit: 29 Sept 2024 (T+90)
  • ●
    Executives
    0DART
    0KRXDART:20231020000458
  • ●
    대표이사 사장Executives
    0DART
    ShareKRXDART:20231005000285
  • ●
    Executives
    0DART
    0KRXDART:20230904000192
  • ●
    Executives
    0DART
    0KRXDART:20230724000222
  • ●
    Executives
    0DART
    0KRXDART:20230711000235
  • ●
    Executives
    0DART
    0KRXDART:20230629000521
  • ●
    Executives
    0DART
    0KRXDART:20230623000560
  • ●
    대표이사 사장Executives
    0DART
    ShareKRXDART:20230621000301
  • ●
    대표이사 사장Executives
    0DART
    ShareKRXDART:20230621000297

25 of 69 declarations

About Yuyu Pharma, Inc.

유유제약 is a South Korean pharmaceutical company focused on the development and marketing of medications. It is listed on the KRX.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations